Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page’s displayed release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a minor site maintenance update rather than a change to the trial information.
    Difference
    0.1%
    Check dated 2026-04-26T15:22:02.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    - Site software revision updated to version v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-19T13:38:04.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    48 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-21T19:50:04.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The page revision was updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-07T09:07:29.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 with no changes to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-14T02:15:45.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 on the Study Details page.
    Difference
    0.1%
    Check dated 2026-02-06T17:37:38.000Z thumbnail image

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.